<DOC>
	<DOC>NCT02094430</DOC>
	<brief_summary>The aim of the study is to evaluate clinical pharmacology, efficacy and safety of FGTW in pediatric patients with congenital fibrinogen deficiency.</brief_summary>
	<brief_title>Human Fibrinogen Concentrate (FGTW) in Pediatric Patients With Congenital Fibrinogen Deficiency</brief_title>
	<detailed_description />
	<mesh_term>Afibrinogenemia</mesh_term>
	<criteria>Signed and dated informed consent form by parents or a legal representative Age less or equal to 12 years old Patients with inherited afibrinogenemia or severe inherited hypofibrinogenemia Negative results on HCGbased pregnancy test for females of childbearing potential (presence of menstruation) Dysfibrinogenemia Acquired fibrinogen deficiency Suspected present or past anticoagulation inhibitor Personal history of venous or arterial thrombosis or thromboembolic event Comorbidity with other/unrelated coagulopathies Administration of any fibrinogen concentrate or fibrinogen containing blood product during the last 15 days Permanent treatment with antithrombotic or antiplatelet agents such as heparins, antiIIa or antiXa agents, aspirin, clopidogrel and NSAIDs.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>